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Policy Forum
This is the second of three articles in the November 
2007 issue on developing new drug treatments for 
tuberculosis.
Current Treatment for 
Tuberculosis and Research Agenda
The standard preferred regimen for 
the treatment of drug-susceptible 
tuberculosis (TB) around the world 
consists of a two-month induction 
phase of isoniazid, rifampin, 
pyrazinamide, and ethambutol followed 
by a continuation phase of four 
months of isoniazid and rifampin. This 
regimen has several advantages: (1) 
it is essentially completely effective in 
achieving sputum culture conversion; 
(2) it is relatively inexpensive and 
universally available; (3) the relapse 
rate is low, at 3%–5%; and (4) it can be 
administered largely intermittently. But 
the regimen has signiﬁcant limitations, 
listed in Box 1.
These limitations can only be 
overcome by building TB clinical trials 
capacity. Trials are urgently needed 
to ﬁnd regimens that are shorter, less 
toxic, and effective against multidrug-
resistant TB (MDR-TB; Figure 1) and 
extensively drug-resistant TB (XDR-
TB). TB treatment regimens must be 
tested in special populations: people 
with HIV infection, including those on 
antiretroviral (ARV) therapy, children, 
and patients with extrapulmonary 
TB. Because of the rapidly evolving 
nature of the global tuberculosis 
epidemic, with increasing numbers 
of HIV-associated cases of TB, more 
drug resistance, and several new drug 
candidates, we will need to ﬁnd ways to 
evaluate new regimens more quickly, 
for example through identifying new, 
robust biomarkers.
A few recent, small-scale trials 
provide an indication of possible new 
treatment regimens, but many types of 
investigations still need to be carried 
out (Table 1). The promising early 
ﬁndings and unresolved (or even 
unasked) questions require further 
examination and reﬁnement, which 
could be done today if the resources 
were available to build clinical trials 
capacity in high-burden countries.
What Is Needed to Build Clinical 
Trial Capacity
The experience of the British Medical 
Research Council’s TB research units 
provides a useful template for planning 
the renewal of capacity for clinical trials 
in TB [1]. Over 40 years, the Medical 
Research Council evaluated all the 
drugs currently in use for the treatment 
of TB. To do this, they tested roughly 
250 different regimens, enrolling 
over 25,000 patients in trials. Why so 
many? Patients with TB are treated 
with regimens, not individual drugs. 
Even if a single new drug is approved 
for the treatment of TB, ﬁnding its 
optimal dosage, dosing frequency, and 
companion drugs will require several 
trials.
Many questions need to be answered 
through a variety of clinical trials as 
described in Table 2. For example, 
moxiﬂoxacin and gatiﬂoxacin are 
promising compounds that provide 
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Summary Points
u The long duration of TB therapy, the 
high prevalence of HIV coinfection, 
and the growing prevalence of drug-
resistant TB strains underscore the 
urgent need for better and more 
effective treatment approaches.
u To improve TB treatment in the near 
future, a large number of clinical trials 
should be carried out to examine 
alternative regimens using existing 
drugs (dosage changes, frequency 
of dosing, etc.) and the modest but 
growing pipeline of new compounds.
u The capacity to conduct a serious 
clinical trials agenda in high-burden 
countries needs to be built up as soon 
as possible.
u Funding on the order of US$300–
US$500 million annually will be 
needed to conduct such a clinical trials 
agenda, including the evaluation of 
new drugs.
u Direct investment must be made in 
the infrastructure needed to conduct 
trials, rather than taking a product-by-
product approach.
The Policy Forum allows health policy makers around 
the world to discuss challenges and opportunities for 
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faster time to culture conversion 
in patients with pulmonary TB [2]. 
Moxiﬂoxacin appears in animal models 
to be more effective when substituted 
for, rather than added to, isoniazid in 
the intensive phase of chemotherapy. 
Also, in a phase II study conducted 
in 217 patients with TB in South 
Africa, substitution of ethambutol 
with gatiﬂoxacin or moxiﬂoxacin was 
associated with enhanced early and 
late sterilizing activity [3]. The optimal 
rifamycin with which to combine 
therapy may be rifapentine rather than 
rifampin [4].
Sample sizes for TB trials (especially 
phase III trials) are quite large because 
current TB treatment, though complex 
and prolonged, is associated with a low 
relapse rate. So signiﬁcant numbers of 
patients are required to ensure with a 
high degree of conﬁdence that newer 
regimens are at least as effective and 
associated with the same or lower rate 
of adverse drug effects as existing 
regimens. Based on the analysis of 
previous trials conducted by the British 
Medical Research Council and the 
TB Trials Consortium of the United 
States Centers for Disease Control 
and Prevention, capacity must exist to 
enroll 3,000–5,000 patients per year in 
phase II and III trials, for each of the 
seven to ten compounds currently in 
clinical development, if TB treatment 
is to be substantially improved in the 
next ﬁve to ten years. However, neither 
the infrastructure nor ﬁnancial support 
exists on the scale needed to carry out 
these important high-quality clinical 
trials.
Infrastructure needs. TB trials can be 
effectively carried out by collaborations 
between front-line providers in high-
burden countries and academic 
institutions that can provide technical 
support and assistance in study design, 
data analysis, drug procurement, and 
training of research personnel. The 
regulatory and ethical requirements 
that now exist for clinical research 
demand that trials be carried out 
according to high standards, without 
compromise on scientiﬁc or moral 
grounds.
Box 2 lists the factors that are needed 
to properly conduct TB trials. These 
needs are especially acute in many 
high-burden countries where there is 
no established research infrastructure 
and where capacity for ethical and 
regulatory review may be limited and 
may face special challenges. Effective 
programs for delivering TB treatment 
exist in many places, but such programs 
are not equivalent to a clinical trials 
infrastructure. Furthermore, creating 
an enduring infrastructure would 
increase the speed and efﬁciency with 
which trials can be conducted. Several 
consortia are currently managing 
to carry out clinical trials, but with 
minimal coordination and inadequate 
ﬁnancial support. With greater support 
and coordination, these consortia 
can expand trials capacity through 
standardized approaches to trial design, 
by providing training (especially 
in high-burden countries), and by 
establishing working relations with 
the regulatory agencies overseeing the 
introduction of new drugs in locations 
around the world.
Limited capacity exists today for 
conducting clinical trials at good 
clinical practice standards. The Global 
Alliance for TB Drug Development 
recently completed a survey of 51 
potential sites where clinical trials for 
TB might be carried out. Preliminary 
results indicate that only a few sites 
around the world, most notably Rio 
de Janeiro, Brazil and Durban, South 
Africa, have the needed components 
and experience to begin enrolling 
patients in signiﬁcant numbers.
Funding. Funding for overall TB 
drug development is at pitifully 
low levels, and for clinical trials 
it is even worse. A report by the 
Treatment Action Group describes 
a comprehensive global survey of 
funding for TB research [5]. Around 
the world in 2005, only US$120 million 
was spent for research on TB drug 
development, and the amount of 
that total which was devoted to actual 
clinical trials was no more than US$20–
US$30 million. The US National 
Institutes of Health (NIH) support the 
Tuberculosis Research Unit, whose 
primary mission is to study immune 
mechanisms in patients with TB rather 
than carrying out clinical trials of TB 
drugs. The US Centers for Disease 
doi:10.1371/journal.pmed.0040302.g001
Figure 1. A Patient with MDR-TB Holds the Dose of Drugs He Must Take Every Day
This patient checked into the hospital in November 2006 and in January 2007 he tested negative; if 
his progress continues, he could be sent home to ﬁnish his treatment. (Photo: Jean-Marc Giboux)
Box 1. Limitations of the 
Standard TB Treatment 
Regimen
u Adverse effects are common—the 
most important adverse effect is 
hepatotoxicity, which can be serious 
and fatal
u Difﬁcult to administer concurrently 
with many ARV drugs
u High rates of nonadherence if self-
administered
u Relapse rates in certain subsets of 
patients (e.g., those with extensive 
cavitary inﬁltrates) may be 15% or 
more
u The regimen is not useful against MDR 
or XDR strains.PLoS Medicine  |  www.plosmedicine.org 1728 November 2007  |  Volume 4  |  Issue 11  |  e302
Control and Prevention created and 
fully supports the TB Trials Consortium 
with a budget of only US$9.2 million 
a year. The European and Developing 
Countries Clinical Trials Partnership 
has spent very little on TB up until now, 
but expects to spend an extra sum of 
US$38 million by 2010, with additional 
funds to support clinical trials capacity 
development in African trials. Monies 
from some pharmaceutical companies, 
and from the Global Alliance for TB 
Drug Development (which is mostly 
funded through the Bill & Melinda 
Gates Foundation with additional 
support from a few European 
countries), comprise the bulk of the 
rest of the funding support.
The Treatment Action Group report 
points out that in the United States, 
the NIH alone spent US$2.9 billion on 
research related to HIV/AIDS in 2005. 
At least US$300 million of this funding 
directly supported clinical trials, mainly 
through large and well-organized 
consortia such as the AIDS Clinical 
Trials Group and the Community 
Programs for Clinical Research on 
AIDS. Biodefense spending by NIH 
exceeds the total expenditure on 
research for TB, which is the only 
disease on their list of perceived threats 
that actually takes millions of lives each 
year. In 2005, for example, NIH spent 
US$187 million and US$183 million 
on research on smallpox and anthrax, 
respectively, and only US$157 million 
on TB.
Based on the experiences of groups 
currently conducting trials, the 
estimated costs for the TB trials work 
needed to create new regimens and 
regimens useful against MDR- and 
XDR-TB considerably exceed current 
spending. Based on the actual costs 
of trials conducted in the past few 
years by the TB Trials Consortium, 
the European Union–funded 
consortium of ten European and 
African institutions (the OFLOTUB 
consortium), and the Johns Hopkins 
TB Research Center, establishing 
infrastructure for 25 sites with 
appropriate clinical, laboratory, and 
regulatory expertise will be on the 
order of US$1–US$2 million per site 
per year, while costs for actual trials will 
range between US$4,000–US$12,000 
per patient, depending on the exact 
location of the study (personal 
communication, N. Schluger, C. 
Leinhardt, and R. Chaisson).
Conclusion
An urgent and massive expansion of 
clinical trials capacity is needed to 
carry out vital research to accelerate 
the development and evaluation of 
new TB drugs, including those active 
against MDR-TB. To conduct the 
clinical trials agenda described above, 
including the evaluation of new drugs, 
funding of at least US$300–US$500 
million annually is needed. It is also 
important to make direct investment in 
the infrastructure needed to conduct 
trials, rather than taking a product-
by-product approach. Current global 
plans for TB drug development 
assume that speciﬁc funding is tied to 
individual drugs in the pipeline and 
Table 1. Tuberculosis Trials Needed and Undertaken
TB Trial Needed Trials Already Undertaken Trial Strengths and Weaknesses
To shorten duration of treatment for 
smear-positive pulmonary TB in non-
HIV-infected patients
2002: Randomized clinical trial by TB Research Centre in 
Chennai, India with regimens using the ﬂuoroquinolone 
oﬂoxacin in the intensive phase [6].
Demonstrated low relapse rates with a four-month regimen 
including oﬂoxacin throughout treatment. All four arms of the trial 
included oﬂoxacin, making the general applicability of the results 
difﬁcult to judge.
2006: Twice-weekly rifapentine-containing regimens in murine 
tuberculosis [7].
Higher and more frequent dosing of rifapentine dramatically 
increases its activity, curing mice in as few as three months.
To simplify dosing 2002: Randomized, multicenter, open-label trial in the US and 
Canada comparing rifapentine and isoniazid once a week 
versus rifampicin and isoniazid twice a week [8].
Rifapentine shown to be effective when delivered in a once-weekly 
regimen to patients at low risk for relapse. Optimal dose and 
companion drugs for this drug still need to be identiﬁed.
To investigate treatment of TB in HIV-
infected patients
2005: Cohort study by the Tuberculosis Trials Consortium in 
which rifabutin was substituted for rifampin in order to lessen 
drug interactions [9].
Regimen for HIV-infected patients with TB treated concurrently 
with ARVs demonstrated excellent survival, with markedly reduced 
mortality compared to historical controls. Acquired rifamycin 
resistance was noted, however, in patients with low CD4+ cell 
counts.
To investigate treatment of MDR- and 
XDR-TB
None have been undertaken, but there are trials planned for 
the compounds TMC207 (Tibotec) and OPC67683 (Otsuka) and 
the antibiotic linezolid.
To investigate treatment regimens for 
children
None have ever been undertaken.
This is not intended as a comprehensive review, but rather as a sampling of trials already undertaken and the types of trials that need to be undertaken on a large scale.
doi:10.1371/journal.pmed.0040302.t001
Table 2. Types of Tuberculosis Clinical Trials
Type Endpoint Size Duration of Study What Is Being Studied?
Phase I Safety/tolerability Small (<50) Days/weeks Drug
PK/PD Pharmacokinetic/pharmacodynamic data; drug interactions Small (<50) Days/weeks Drug(s)
Phase IIa Early bactericidal activity  Small (50–100) Days/weeks Drug
Phase IIb Two-month culture conversion; time to culture conversion; 
serial sputum colony counts
Medium (100–300) Months Regimen
Phase III Failure/relapse Large (>1,000) Years Regimen
Phase IV Detection of uncommon side effects Large (>1,000) Years Regimen
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does not take into account the need 
for trials for MDR-TB. We believe that 
this product-by-product approach will 
lead to inefﬁciency, redundancy, and 
wasted time, and will fail to address the 
important question of how to construct 
regimens. Independent support for 
clinical trial sites that are prepared 
to undertake a variety of studies is 
essential to ensure that new regimens 
are developed as quickly as possible. A 
strategy where strong clinical trial sites 
are funded to build capacity to support 
weaker centers will ensure increased 
and sustained capacity to conduct more 
trials in less time.
A large number of clinical trials with 
the potential to signiﬁcantly improve 
TB treatment in the very near future 
can be carried out right now. As new 
drugs move through the pipeline, 
the trials agenda will grow rapidly. A 
network of existing consortia should be 
created to develop uniform standards 
and platforms for conducting this trials 
agenda and to coordinate the various 
trial activities. Most important, a massive 
increase in funding, from public and 
philanthropic sources, is urgently 
needed for clinical trial sites, in order to 
reduce the global burden of TB and to 
improve the lives of patients with TB.  
Acknowledgments
The authors wish to thank Kevin P. Q. 
Phelan, MA for editorial support.
References
1. Fox W, Ellard GA, Mitchison DA (1999) 
Studies on the treatment of tuberculosis 
undertaken by the British Medical Research 
Council tuberculosis units, 1946–1986, with 
relevant subsequent publications. Int J Tuberc 
Lung Dis 3: S231–S279.
2. Burman WJ, Goldberg S, Johnson JL, Muzanye 
G, Engle M, et al. (2006) Moxiﬂoxacin versus 
ethambutol in the ﬁrst 2 months of treatment 
for pulmonary tuberculosis. Am J Respir Crit 
Care Med 174: 331–338.
3. Lienhardt C, Rustomjee R, Allen J, Mthiyane T, 
Levin J, et al. (2005) Comparison of 2-months 
sterilizing activities of several quinolone-
containing regimens for the treatement of 
TB [poster LBII-13]. Interscience Conference 
on Antimicrobial Agents and Chemotherapy; 
Washington, D. C., United States of America; 
16–19 December 2005. 
4. Nuermberger EL, Yoshimatsu T, Tyagi 
S, Williams K, Rosenthal I, et al. (2004) 
Moxiﬂoxacin-containing regimens of reduced 
duration produce a stable cure in murine 
tuberculosis. Am J Respir Crit Care Med 170: 
1131–1134.
5. Feuer C (2006) Tuberculosis research and 
development: A critical analysis. Treatment 
Action Group. Available: http:// www.
aidsinfonyc.org/tag/tbhiv/tbrandd.pdf.
Accessed 7 October 2007.
6. Narayanan P (2002) Shortening short course 
chemotherapy: A randomized clinical trial 
for treatment of smear positive pulmonary 
tuberculosis with regimens using oﬂoxacin 
in the intensive phase. Indian J Tuberc 49: 
27–38.
7. Rosenthal IM, Williams K, Tyagi S, Peloquin 
CA, Vernon AA, et al. (2006) Potent twice-
weekly rifapentine-containing regimens in 
murine tuberculosis. Am J Respir Crit Care 
Med 174: 94–101.
8. Benator D, Bhattacharya M, Bozeman L, 
Burman W, Cantazaro A, et al. (2002) 
Rifapentine and isoniazid once a week versus 
rifampicin and isoniazid twice a week for 
treatment of drug-susceptible pulmonary 
tuberculosis in HIV-negative patients: A 
randomised clinical trial. Lancet 360: 528–534
9. Burman W, Benator D, Vernon A, Khan A, 
Jones B, et al. (2006) Acquired rifamycin 
resistance with twice-weekly treatment of HIV-
related tuberculosis. Am J Respir Crit Care 
Med 173: 350–356.
Building research capacity and 
infrastructure in both high- and low-
burden countries requires a signiﬁcant 
initial investment of funds, but is extremely 
cost-effective in the long run, as it allows 
for the creation of a stable and well-trained 
cohort of investigators and nurses as well 
as mechanisms for rapid development and 
evaluation of a series of research protocols, 
without the need to recreate these 
components each time a trial is proposed.
Infrastructure Needed in Both High- 
and Low-Burden Countries
u Physicians and nurses experienced in 
caring for patients with TB and trained 
in clinical research
u Field workers to assist with therapy 
and assure that study regimens are 
followed correctly
u Institutional review boards/ethics 
committees that review proposals in 
an informed and timely manner
u Regulatory experts to aid in moving 
new compounds through the varied 
and complex regulations governing 
the use of experimental drugs in many 
different countries
u Well-equipped and functioning 
laboratories with capacity for 
performing culture and susceptibility 
testing on clinical isolates (or capacity 
for shipping to central laboratories that 
have this capacity)
u Site monitoring capability and the 
logistical capacity to ensure that the 
quality of all of the above is maintained 
throughout
Infrastructure Needed in Low-Burden 
Countries Only
u Experienced biostatisticians to support 
trial design, statistical analysis, and 
data monitoring
Box 2. Infrastructure Needed in High- and Low-Burden Countries 
for Conducting TB Trials